Medigene is developing Living Immunotherapies, with the goal of providing revolutionizing cancer treatments that offer a higher quality of life for patients.
We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.
Please contact our business development team if you are interested in discussing our clinical programs or want to develop new innovative immunotherapies based on our technologies to optimally tackle specific tumor types.
Dr. Rolf Kalhammer
Vice President, Head of Business Development
Telephone: +49-89-20 00 33-33 06
Fax: +49-89-20 00 33-29 20
Developmental and Commercial Partnerships
In order to change the paradigm of cancer treatment, Medigene seeks partnerships with other leaders in the field to exploit the full potential of our immunotherapy technology platforms. Therefore, we are already collaborating with industry leaders:
bluebird bio, Inc., USA.
In September 2016, bluebird bio and Medigene established a strategic T cell receptor (TCR) alliance in cancer immunotherapy. The strategic research and development collaboration and licensing agreement encompasses T cell receptor (TCR) immunotherapies against four targets. Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates and will receive an exclusive license for the intellectual property covering the resulting TCRs.
EUFETS GmbH, Germany
Medigene has signed an agreement with the contract manufacturer EUFETS GmbH in February 2016 for the production and delivery of viral vectors and cellular therapeutic products. EUFETS is an experienced contract manufacturing organization (CMO) that will take over further process development tasks and vector optimization processes, the establishment of different cell banks, and the batch production of viral vectors for Medigene's T cell receptor (TCR) based cancer therapies. In addition, EUFETS serves as contract manufacturer for patient-individualized TCR therapeutics for use in clinical studies.
In order to support the development of our research projects, we have built an international scientific network through partnerships. Academic and clinical contacts and collaborations have been established with leading hospitals and institutions in Europe and in North America, such as:
Charité - Universitätsmedizin Berlin (Charité), Germany:
Max-Delbrück-Centre for Molecular Medicine in the Helmholtz-Gemeinschaft (MDC)
University Lausanne, Switzerland
University Hospital Oslo, Norway
Partnerships for non-core products
Veregen®: Distribution rights granted to various marketing partners
Medigene generates revenue from royalties, product sales, and milestone payments of Veregen®, a drug for the treatment of genital warts. Veregen® is based on a defined extract from green tea leaves and is currently available in the USA and Canada, in 20 European countries, and in Taiwan. Numerous marketing agreements for Veregen® are in place with international distribution partners:
In December 2017, Medigene sold the US rights of Veregen® to Fougera Pharmaceuticals, USA, and still holds all rights outside the US.
If you have any questions regarding marketing partnerships for our marketed products, please contact Michaela Fabry, Commercial Operations.
Telephone: +49-89-20 00 33-29 56
Fax: +49-89-20 00 33-29 20
RhuDex®: Outlicensed to Dr. Falk Pharma GmbH
RhuDex® is an oral, disease modifying agent to treat autoimmune diseases. It is a CD80 antagonist that blocks undesired T-cell activation and production and therefore has both an immune-modulating and anti-inflammatory effect. The safety and tolerability of RhuDex® have been demonstrated in a number of Phase I clinical trials. Medigene has successfully completed a pilot Phase IIa trial in the indication rheumatoid arthritis. In 2013, Medigene outlined preparations for a further clinical development of RhuDex® in the indication of primary biliary cirrhosis (PBC).
In March 2014, Medigene signed a license agreement with the pharmaceutical company Dr. Falk Pharma GmbH, Freiburg, for the development and marketing rights to RhuDex® for hepatology and gastroenterology indications. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas.
Falk Pharma has initially concentrated on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in rheumatoid arthritis, psoriasis and other autoimmune diseases.